Table 1 Baseline characteristics
Baseline characteristics | G-CSF only (n= 33) | CY+G-CSF (n= 24) | ETO+G-CSF (n= 116) | p-value |
|---|---|---|---|---|
Median age (in years) (range) | 43.0 (17.0–67.0) | 46.5 (20.0–62.0) | 52 (21.0–65.0) | 0.003 |
Male:female ratio | 2.00 | 2.43 | 1.23 | 0.243 |
Histology,n(%) | 0.139 | |||
Hodgkin lymphoma | 3 (9.1) | 4 (16.7) | 5 (4.3) | |
Non-Hodgkin lymphoma | ||||
B cell | 15 (45.5) | 14 (58.3) | 65 (56.0) | |
T cell | 15 (45.5) | 6 (25.0) | 46 (39.7) | |
Disease stage,n(%) | 0.342 | |||
Limited stage (Stage I-II) | 8 (24.2) | 3 (12.5) | 31 (26.7) | |
Advanced stage (Stage III-IV) | 25 (75.8) | 21 (87.5) | 85 (73.3) | |
Bone marrow involvement at dagnosis,n(%) | 5 (15.2) | 6 (25.0) | 30 (27.5) | 0.472 |
Number of previous chemotherapy treatments (range) | 2 (1-3) | 2 (1–3) | 1 (1-5) | 0.139 |
Disease status before mobilization,n(%) | 0.080 | |||
Complete remission | 12 (36.4) | 10 (41.7) | 52 (44.8) | |
Partial remission | 19 (57.6) | 12 (50.0) | 47 (40.5) | |
Dose, total (mg/m2) (range) | ━ | 3,000 (1,000–3,000) | 750 (375–750) | ━ |
Time from diagnosis to start of mobilization (months) (range) | 7.6 (3.7–63.3) | 16.6 (0.7-59.9) | 6.2 (1.5–148.0) | 0.003 |
Median follow-up duration after mobilization (months) (range) | 12.2 (0.1–96.0) | 37.8 (0.1–92.6) | 13.0 (1.4–76.8) | ━ |
Transplantation done,n(%) | 29 (90.6) | 16 (72.7) | 112 (96.6) | ━ |